2514 Phallisacin Phallisacin is a solid exogenous compound with the chemical formula C37H50N8O14S. Phallisacin belongs to the amino acids, peptides, and analogues, a subclass of carboxylic acids and derivatives within the organic compounds. With an average molecular weight of 862.90 g/mol, Phallisacin is a heavy molecule. This compound targets four proteins: Actin, cytoplasmic 1 (ACTB), Actin, cytoplasmic 2 (ACTG1), Actin, alpha skeletal muscle (ACTA1), and Actin, aortic smooth muscle (ACTA2). Phallotoxins bind actin, preventing its depolymerization and poisoning the cell. They bind specifically at the interface between F-actin subunits, locking adjacent subunits together. This leads to a decrease in the rate constant for the dissociation of actin subunits from filament ends, which essentially stabilizes actin filaments through the prevention of filament depolymerization. Moreover, they inhibit the ATP hydrolysis activity of F-actin. 58286-46-7 3045091 C37H50N8O14S 862.9031 White powder. Oral, dermal, inhalation, and parenteral (contaminated drugs). (A3101) Phallotoxins bind actin, preventing its depolymerization and poisoning the cell. They bind specifically at the interface between F-actin subunits, locking adjacent subunits together. This leads to a decrease in the rate constant for the dissociation of actin subunits from filament ends, which essentially stabilizes actin filaments through the prevention of filament depolymerization. Moreover, they inhibit the ATP hydrolysis activity of F-actin. (L1183, A2465) LD50: 4.5 mg/kg (Mouse) (T258) No indication of carcinogenicity to humans (not listed by IARC). Phallacin is one of a group of toxins from the death cap (Amanita phalloides) known as phallotoxins. (L996) Liver lesions, tachycardia, hypoglycemia, hypotension and electrolyte imbalance with acid- base disturbance (L1160). Hypovolemic shock; Gastrointestinal symptoms occur after a latent period and include abdominal pain, vomiting, and watery diarrhea. Neurologic symptoms are related to hepatic failure and may include encephalopathy, somnolence, confusion, coma and seizures (L1160). Consider gastric lavage and activated charcoal. (A678) 2009-07-03T21:46:57Z 2026-08-31T21:59:23Z Phallisacin true CC(C)C1N=C(O)C(CC(O)(CO)CO)N=C(O)C2CC3=C(NC4=CC=CC=C34)SCC(N=C(O)C(N=C1O)C(O)C(O)=O)C(=O)N1CC(O)CC1C(O)=NC(C)C(O)=N2 C37H50N8O14S InChI=1S/C37H50N8O14S/c1-15(2)25-32(54)44-26(27(49)36(57)58)33(55)41-23-12-60-34-19(18-6-4-5-7-20(18)42-34)9-21(29(51)40-22(30(52)43-25)10-37(59,13-46)14-47)39-28(50)16(3)38-31(53)24-8-17(48)11-45(24)35(23)56/h4-7,15-17,21-27,42,46-49,59H,8-14H2,1-3H3,(H,38,53)(H,39,50)(H,40,51)(H,41,55)(H,43,52)(H,44,54)(H,57,58) CUMAQJMTVOVGKD-UHFFFAOYSA-N 862.903 862.316719038 Exogenous Solid -2.6 2307925 CHEM002058 NS00120841 2-[28-[2,3-dihydroxy-2-(hydroxymethyl)propyl]-18-hydroxy-23-methyl-15,21,24,26,29,32,35-heptaoxo-31-propan-2-yl-12-thia-10,16,22,25,27,30,33,36-octazapentacyclo[12.11.11.03,11.04,9.016,20]hexatriaconta-3(11),4,6,8-tetraen-34-yl]-2-hydroxyacetic acid 370.09 209.3450000000001 84.30551473241165 7 20 13 1.8076780589935102 7.276224035527091 -1 5 -0.13 -3.60 2.19e-01 g/l Organic compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues 6 CED0030051 CUMAQJMTVOVGKD-UHFFFAOYSA-N 44200000000000020000800000203100000000044000000000000002110000041002001080000020000010000060003004000000000000000000000800000000000000000000000000020000000000000020000010080000001000001200000000000000010000000080000000001000000008020100000000002000020000100000000040000080c00000200000000000000010000100000000000020400000008c10048020000000040000081010000000000000000000010000000000000000000000040000002004090008000000002008000000000040004200000001000000000008000800000040000000080401000000108400400000220000000000 7006c0708d33c620c9dcd36783f8b288991034ba9517a074cd3c60d4cb30eacc6c7601d913a0244c8542412800c9200097680ba5c0ce723503cf7f7dc0e24124c711948d1ad01400c29013e01af32b604844c59151611fb753544d6654221bb7cde8656f186c3230609a9184ddf40044708692f2899de5a6b17b2e79835119175044181d5ef8a60a0c1f03d0ee2c42a8393cda1645c2be8b70360ca062d8478453d710d309b6d2330b866d68877c3d144ac12243a9498ac858b14ab4cc6a4a12a61110a7bddb53331dc026a6575542990c356014032578628d70f60e2e01030491386d3618c94b2d1b6c2411db56a88e1e5026b492c6842f53999b82da0e0c46 776t3gAAAAAQAAAAAwAAAAAAAAA8AAAAQAAAAIABBgBgAAAAAQMGAGAAAAAD AQYAYAAAAAEDBgBgAAAAAwEHACgAAAADAwYAKAAAAAMECABoAAAAAwEBBgBg AAAAAwEGAGAAAAACAgYAIAAAAAQIAGAAAAABAQYAYAAAAAICCABgAAAAAQEG AGAAAAACAggAYAAAAAEBBwAoAAAAAwMGACgAAAADBAgAaAAAAAMBAQYAYAAA AAMBBgBgAAAAAgIGQCgAAAADBAZAKAAAAAMEB0A4AAAAAwEDBkAoAAAAAwQG QGgAAAADAwEGQGgAAAADAwEGQGgAAAADAwEGQGgAAAADAwEGQCgAAAADBBAA IAAAAAIGAGAAAAACAgYAYAAAAAMBBwAoAAAAAwMGACgAAAADBAgAaAAAAAMB AQYAYAAAAAMBBwAoAAAAAwMGACgAAAADBAgAaAAAAAMBAQYAYAAAAAMBCABg AAAAAQEGACgAAAADBAgAaAAAAAMBAQgAKAAAAAMCBgAoAAAAAwQIACgAAAAD AgcAKAAAAAMDBgBgAAAAAgIGAGAAAAADAQgAYAAAAAEBBgBgAAAAAgIGAGAA AAADAQYAKAAAAAMECABoAAAAAwEBBwAoAAAAAwMGAGAAAAADAQYAYAAAAAED BgAoAAAAAwQIAGgAAAADAQEHACgAAAADAwsAAQABAgABAwADBAAEBSgCBQYg BQcABwgACAkACQoACQsACwwACQ0ADQ4ABw8ADxAoAhARIBASABITABMUABQV aAwVFmgMFhdoDBcYaAwYGWgMGRpoDBobaAwbHGgMFR0AHR4AHh8AHyAAICEo AiEiICEjACMkACQlKAIlJiAjJwAnKAAnKQApKiApKygCHywALC0oAiwuIC4v AC8wADAxADAyADIzADM0ADQ1IDQ2KAI2NwA3OAA3OQA5OiA5OygCJQMAMy4A OxIAHBRoDBwXaAxCBQAAABIDJSQjISAfHh0VFBMSEA8HBQQPExI7OTc2NDMu LB8eHRUUBRYVFBwXBhgZGhscFwUvLjMyMBcEAAAAAAAAABY= 2026-09-19T04:00:28Z